Antigen-Specific Immune Tolerance Platform
Anchored by first-in-class immuno-modulatory allosteric anti-CD40 Ab
Immune tolerance platform
Diabetes Free is a clinical-stage platform biotechnology company focused on antigen-specific immune tolerance anchored by a first-in-class SQ allosteric anti-CD40 mAb across the fields of autoimmunity, particularly multiple sclerosis, gene therapy, and immunosuppression-free islet cell and other transplantation as a functional cure of diabetes, hence the company’s founding mission and name.
Tolerance
Our immuno-modulatory Tolerance platform holds the potential to be used for several applications, including transplantation, gene therapy and for patients with autoimmune disease
Transplantation
IND Enabled
Gene Therapy
AAV Redosing Safety & Efficacy
Autoimmunity
Multiple Sclerosis, Crohn’s, SLE, T1D
TX Competitive Landscape
|
DFI 105
|
Ocrevus
|
Kesimpta
|
Frexalimab
|
|
|---|---|---|---|---|
| target |
Anti-CD40
|
Anti-CD20
|
Anti-CD20
|
Anti-CD40L
|
| stage |
Ph 2 POC Q1 2025
|
Commercial (IV) Approval 2024
|
Commercial
|
Ph 3 Data 2025
|
| route |
SQ (high conc. / low vol. ≥200mg/mL)
|
SQ
|
SQ
|
IV
|
| delivery |
Auto-injector compatibility established
|
Hyaluronidase high vol. depot
|
Home use auto injector
|
Infusion center high volume IV
|
| efficacy |
NHP data consistent with CD40 class effect
|
0.04 ARR
|
0.05 ARR
|
0.04 ARR (Phase 2)
|
| safety |
|
|
|
|
| revenues |
?
|
$7B (2023)
|
$2B (2023)
|
$5B (Sanofi Est.)
|